



VacZine Analytics

Bringing life to vaccine strategy...

DiseaseINFOPACK

Norovirus

September 2008

Abstract

DiseaseINFOPACK: Norovirus

CAT No: VADIP009, published September 2008

REPORT ABSTRACT:

Noroviruses are a group of RNA viruses which are highly infectious and stable in the environment. Mostly transmitted person to person in outbreaks, noroviruses are the leading cause of epidemic nonbacterial gastroenteritis worldwide often affecting the elderly in long-term care facilities and hospitals. Although Noroviruses cause a mild illness of short duration, severe dehydration or electrolyte imbalance can be a contributing cause to death in vulnerable populations. Significantly, current evidence suggests that the magnitude and severity of norovirus epidemics is growing.

This DiseaseINFOPACK report is an expert review of the current literature (September 2008) providing the reader with a full easy-to-read overview of the pathogen, its epidemiology, through to its clinical impact and current management. The report also includes analysis of current disease trends and future dynamics.

PAGES: 36

Table of contents

Executive summary

Author's note

The pathogen

Genogroups

Clinical features

Pathogenesis

Host response

Transmission

Risk groups for NV*

Prevention and control

Diagnosis

Treatment

Morbidity

Mortality

Surveillance

Incidence – US

Incidence – Germany

Incidence – England & Wales

Incidence by age – EU

Incidence by setting – EU

Global morbidity/mortality

Estimating global morbidity/mortality

Economic impact

Estimating economic impact

Opportunities for new treatments

Key disease trends and dynamics

Bibliography

About VacZine Analytics

Bibliography

1. Teunis PF et al. Norwalk virus: how infectious is it? *J Med Virol*. 2008 Aug;80(8):1468-76.
2. US Centers for Disease Control and Prevention. Norovirus: Technical Fact Sheet. Available at: www.cdc.gov. Accessed: Sep 2008
3. Lamhoujeb S et al. Evaluation of the persistence of infectious human noroviruses on food surfaces by using real-time nucleic acid sequence-based amplification. *Appl Environ Microbiol*. 2008 Jun;74(11):3349-55
4. Ngazoa ES et al. Quantitative study of persistence of human norovirus genome in water using TaqMan real-time RT-PCR. *J Appl Microbiol*. 2008 Mar;104(3):707
5. Jansen A et al. [The norovirus-epidemic in Berlin - clinic, epidemiology, and prevention]. *Z Gastroenterol*. 2004 Apr;42(4):311-6.
6. Lynn S et al. Norovirus outbreaks in a hospital setting: the role of infection control. *N Z Med J*. 2004 Feb 20;117(1189):U771.
7. Siebenga J et al. Epochal evolution of GGII.4 norovirus capsid proteins from 1995 to 2006. *J Virol*. 2007 Sep;81(18):9932-41.
8. Bon F et al. Molecular epidemiology of caliciviruses detected in sporadic and outbreak cases of gastroenteritis in France from December 1998 to February 2004. *J Clin Microbiol*. 2005 Sep;43(9):4659-64.
9. Siebenga J et al. Food-borne viruses in Europe network report. *Euro Surveill*. 2008 Jan 10;13(2). pii: 8009.
10. Tu ET et al. Epidemics of gastroenteritis during 2006 were associated with the spread of norovirus GII.4 variants 2006a and 2006b. *Clin Infect Dis*. 2008 Feb 1;46(3):413-20.
11. Blanton LH et al. Molecular and epidemiologic trends of caliciviruses associated with outbreaks of acute gastroenteritis in the United States, 2000-2004. *J Infect Dis*. 2006 Feb 1;193(3):413-21.
12. Lopman, B et al. Increase in viral gastroenteritis outbreaks in Europe and epidemic spread of new norovirus variant. *Lancet*. 2004 Feb 28;363(9410):682-8.
13. Lee N et al. Fecal viral concentration and diarrhea in norovirus gastroenteritis. *Emerg Infect Dis*. 2007 Sep;13(9):1399-401.
14. Meeting report from the Third European Congress of Virology, 1-5 September 2007 in Nuremberg, Germany. *Euro Surveill*. 2007;12(12):pii=757
15. Lopman B et al. The evolution of norovirus, the "gastric flu." *PLoS Med*. 2008 Feb;5(2):e42.
16. Narkeviciute I et al. Peculiarities of norovirus and rotavirus infections in hospitalized young children. *J Pediatr Gastroenterol Nutr*. 2008 Mar;46(3):289-92.
17. Mattner F et al. Risk groups for clinical complications of norovirus infections: an outbreak investigation. *Clin Microbiol Infect*. 2006 Jan;12(1):69-74.
18. Lopman BA et al. Clinical manifestation of norovirus gastroenteritis in health care settings. *Clin Infect Dis*. 2004 Aug 1;39(3):318-24.
19. Treanor JJ, et al. Noroviruses and other caliciviruses. In: Mandell GL et al. Principles and practice of infectious diseases. Ed 6. Philadelphia: Elsevier Churchill Livingstone, 2005;2:2194-201
20. Marionneau S et al. Norwalk virus binds to histo-blood group antigens present on gastroduodenal epithelial cells of secretor individuals. *Gastroenterology*. 2002 Jun;122(7):1967-77
21. Hutson AM et al. Norwalk virus-like particle hemagglutination by binding to h histo-blood group antigens. *J Virol*. 2003 Jan;77(1):405-15.
22. Parrino TA et al. Clinical immunity in acute gastroenteritis caused by Norwalk agent. *N Engl J Med* 1977;297:86--9.
23. Johnson PC et al. Multiple challenge study of host susceptibility to Norwalk gastroenteritis in US adults. *J Infect Dis* 1990; 161:18-24.
24. Rockx BH et al. Association of histo-blood group antigens and susceptibility to norovirus infection. *J Infect Dis* 2005;191(5):749-54
25. Lindesmith LC et al. Mechanisms of GII.4 norovirus persistence in human populations. *PLoS Med*. 2008 Feb;5(2):e31.
26. Halperin T et al. E. No association between histo-blood group antigens and susceptibility to clinical infections with genogroup II norovirus. *J Infect Dis*. 2008 Jan 1;197(1):63
27. Chachu KA et al. Antibody is critical for the clearance of murine norovirus infection. *J Virol*. 2008 Jul;82(13):6610-7.

Bibliography (cont..)

28. Siebenga JJ et al. High Prevalence of Prolonged Norovirus Shedding and Illness among Hospitalized Patients: A Model for In Vivo Molecular Evolution. *J Infect Dis.* 2008 Oct 1;198(7):994-1001.
29. Widdowson MA et al . Are noroviruses emerging? *Emerg Infect Dis.* 2005 May;11(5):735-7
30. Ko G et al. Noroviruses as a cause of traveler's diarrhea among students from the United States visiting Mexico. *J Clin Microbiol.* 2005 Dec;43(12):6126-9.
31. Nakagomi T et al. Norovirus infection among children with acute gastroenteritis in Recife, Brazil: disease severity is comparable to rotavirus gastroenteritis. *Arch Virol.* 2008;153(5):957-60.
32. Chhabra P et al. Norovirus genotype IIb associated acute gastroenteritis in India. *J Clin Virol.* 2008 Aug;42(4):429-32.
33. German Federal Health Monitoring. Notifiable Diseases. Available at: <http://www.gbe-bund.de> Accessed: September 2008
34. Patel MM et al. Systematic literature review of role of noroviruses in sporadic gastroenteritis. *Emerg Infect Dis.* 2008 Aug;14(8):1224-31
35. Calderon-Margalit R et al. A large-scale gastroenteritis outbreak associated with Norovirus in nursing homes. *Epidemiol Infect.* 2005 Feb;133(1):35-40.
36. Rotavirus and Rotavirus Vaccine Epidemiology and Prevention of Vaccine-Preventable Diseases. National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention Revised March 2008. Available at: www.cdc.gov. Accessed September 2008.
37. MMWR. Norovirus Activity --- United States, 2006—2007. August 24, 2007 / 56(33):842-846
38. Okada M et al. Shinozaki K (2006) Genetic analysis of noroviruses associated with fatalities in healthcare facilities. *Arch Virol* 151: 1635-1641.
40. HPA. Guidance for the Management of Norovirus Infection in Cruise Ships. 13 July 2007. Available at: <http://www.hpa.org.uk> Accessed: September 2008
41. Motomura K et al. Identification of Monomorphic and Divergent Haplotypes in 2006/2007 Norovirus GII/4 Epidemic Population by Genome-wide Tracing of Evolutionary History. *J Virol.* 2008 Sep 4.
42. Health Protection Agency. Norovirus Laboratory reports of all identifications by age, 1992 – 2006. Available at: <http://www.hpa.org.uk/>. Accessed: September 2008
43. HPA. Norovirus update December 2007. Available at: <http://www.hpa.org.uk/>. Accessed: September 2008.
44. Krause G et al. SurvNet electronic surveillance system for infectious disease outbreaks, Germany. *Emerg Infect Dis.* 2007 Oct;13(10):1548-55.
45. Chan MC et al. Fecal viral load and norovirus-associated gastroenteritis. *Emerg Infect Dis.* 2006 Aug;12(8):1278-80.
46. van Duynhoven YT et al. A one-year intensified study of outbreaks of gastroenteritis in The Netherlands. *Epidemiol Infect.* 2005 Feb;133(1):9-21.
47. Health Protection Agency. Norovirus Laboratory reports of all identifications by age, 1992 – 2006. Available at: <http://www.hpa.org.uk/>. Accessed: September 2008
48. HPA. Norovirus update December 2007. Available at: <http://www.hpa.org.uk/>. Accessed: September 2008.
49. Krause G et al. SurvNet electronic surveillance system for infectious disease outbreaks, Germany. *Emerg Infect Dis.* 2007 Oct;13(10):1548-55.
50. Chan MC et al. Fecal viral load and norovirus-associated gastroenteritis. *Emerg Infect Dis.* 2006 Aug;12(8):1278-80.
51. van Duynhoven YT et al. A one-year intensified study of outbreaks of gastroenteritis in The Netherlands. *Epidemiol Infect.* 2005 Feb;133(1):9-21.
52. Bed availability and occupancy, England, 2003-04: Available at <http://www.performance.doh.gov.uk>. Accessed September 2008
53. Ligocyte. Norovirus vaccine. Available at: <http://www.ligocyte.com/>. Accessed: September 2008

About VacZine Analytics:

VacZine Analytics is a brand new research consultancy based in the United Kingdom. Its aim is to provide high quality-disease and commercial analysis to those working within or in collaboration with the vaccine industry.

- With our product lines:
 - DiseaseINFOPACK
 - OpportunitySCAN
 - MarketVIEW
 - ExpertREACT
 - VaccineSTATS

Our key focus is helping clients to build the case for developing new vaccines.

Disclaimer

All rights reserved

This licensed product (or part thereof) may not be reproduced, stored in a retrieval system or transmitted in any form without the written permission of the publisher VacZine Analytics (a division of Assay Advantage Ltd).

The facts presented within this document, at the time of its production, were believed to be correct and were gathered in good faith from both primary and secondary sources. VacZine Analytics is not always in the position to assure that the facts are guaranteed. VacZine Analytics cannot be held liable for any actions based upon facts or recommendations presented within this document.



VacZine Analytics

Bringing life to vaccine strategy...

www.vacZine-analytics.com

Warren House

Bells Hill

Bishops Stortford

Herts

CM23 2NN

United Kingdom

Tel. +44 (0) 1279 654514

e-mail: info@vacZine-analytics.com